Eflapegrastim

(Rolvedon®)

Rolvedon®

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous; 13.2 mg/0.6 mL)
Drug ClassLeukocyte growth factors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Product Monograph / Prescribing Information

Document TitleYearSource
Rolvedon (eflapegrastim-xnst) Prescribing Information. 2022Spectrum Pharmaceuticals Inc., Irvine, CA

Systematic Reviews / Meta-Analyses